Pyrazole Hsp90 Inhibitors Disrupt Oncogenic Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic agents for cancer are unsatisfactory due to their inability to effectively target the complex network of signaling pathways involved in malignant cancers, leading to multidrug resistance and poor prognosis for cancer patients.
Innovation Solution
Development of novel compounds that inhibit Hsp90 activity, leading to the degradation of Hsp90 client proteins such as Her2, Akt kinase, and other oncogenic proteins, thereby simultaneously disrupting multiple pathways involved in cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chemotherapeutic agents are used to treat cancer, then they target a specific molecular target, but they fail to effectively disrupt the complex network of signaling pathways involved in malignant cancers
Solution Approach 1:
The patent applies universality by designing Hsp90 inhibitors that simultaneously target multiple client proteins and signaling pathways. Hsp90 is a central chaperone protein that stabilizes numerous oncogenic client proteins including Her2, Akt kinase, Cdk4/cyclin D complexes, Raf-1, and v-src. By inhibiting Hsp90, a single agent can disrupt multiple parallel signaling pathways involved in cancer progression, transforming a single-target approach into a multi-functional therapeutic strategy that addresses the complexity of cancer signaling networks
2Device complexity
If chemotherapeutic agents target a single molecular target, then the treatment mechanism is simple, but multidrug resistance develops and prognosis remains poor
Solution Approach 1:
The patent merges multiple therapeutic effects into a single Hsp90 inhibition mechanism. By targeting Hsp90, the treatment simultaneously affects multiple client proteins and signaling pathways that are critical for cancer cell survival. This convergence of multiple anti-cancer effects into one mechanism maintains simplicity while overcoming the limitations of single-target therapies, preventing multidrug resistance by disrupting the coordinated function of multiple oncogenic proteins
Data Source
AI summary
Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell.Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.